Citizen Portal
Sign In

Get Full Government Meeting Transcripts, Videos, & Alerts Forever!

Get email alerts on the Prepackaging Hb3361 topic

No spam. Unsubscribe anytime.

Patients and small growers warn OMMA prepackaging rule will harm medicine quality and mom-and-pop businesses

Oklahoma Medical Marijuana Authority · December 19, 2024
AI-Generated Content: All content on this page was generated by AI to highlight key points from the meeting. For complete details and context, we recommend watching the full video. so we can fix them.

Summary

Patients, dispensary operators and growers told OMMA that House Bill 3361–driven prepackaging rules risk increased mold, loss of ability to inspect products, burdensome labeling and extra costs that could push customers to the black market and strain small operators.

Patients, family-run dispensaries and legacy growers told the Oklahoma Medical Marijuana Authority on Dec. 17 that the agency’s proposed implementation of House Bill 3361 requiring prepackaged cannabis flower could harm product quality and small businesses.

"Our patients who come to us are already sick," said Tracy Turner, a dispensary operator and patient, who warned that prepackaged flower that cannot be burped or inspected increases the risk of mildew and mold. "I can't consciously sell them something that I know can make them more sick."

Several speakers said prepackaging would remove the customer’s—particularly patients’—ability to see or smell product before purchase, reduce freshness, and create inventory and labeling burdens for small growers. "Having everything prepackaged will not only degrade the cannabis itself, but have all of your patients going back to the black market," Turner said.

Industry commenters proposed mitigations. Speakers recommended an approved pesticide list to limit repeated rule changes, adoption of QR codes to show biomass provenance, allowance for processors to return packaged flower to original licensees, and flexible relabeling (sticker-on-sticker) to avoid wasting packaging.

Multiple patient advocates contrasted Oklahoma with other states that allow broader testing and argued protections for product quality and patient choice must accompany any prepackaging mandate.

Next steps: OMMA staff reminded attendees that written agency responses will be provided to all commenters and the written public comment period remained open through 5 p.m. on Dec. 17.